SCHEMBL1300632

SCHEMBL1300632

Cc1nc(-c2cccc(CO)c2)no1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.70
S1PR1 P21453 2/20 0.56
S1PR3 Q99500 1/20 0.56
DAO P14920 1/20 0.52
MET P08581 1/20 0.49
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
MAPK1 P28482 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
FFAR4 Q5NUL3 1/20 0.47
PRKCI P41743 1/20 0.46
HCRTR1 O43613 3/20 0.46
HCRTR2 O43614 3/20 0.46
SLC6A4 P31645 1/20 0.46
TSHR P16473 1/20 0.46
NOTUM Q6P988 1/20 0.45
MAPT P10636 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10066488 0.86 L3MBTL1 (0.72) L3MBTL1S1PR1S1PR3DAOMET
SCHEMBL1301049 0.84 L3MBTL1 (0.70) L3MBTL1S1PR1S1PR3DAOMET
SCHEMBL15265754 0.84 L3MBTL1 (0.70) L3MBTL1S1PR1S1PR3DAOMET
Hydrochloric Acid SCHEMBL6565113 0.83 L3MBTL1 (0.68) L3MBTL1S1PR1S1PR3DAOMET
SCHEMBL13130238 0.83 L3MBTL1 (1.00) L3MBTL1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL20368108 0.82 S1PR1 (0.65) L3MBTL1S1PR1S1PR3NPC1RAB9A
Hydrochloric Acid SCHEMBL31346661 0.82 L3MBTL1 (0.62) L3MBTL1DAOMETNPC1RAB9A
SCHEMBL12747582 0.82 L3MBTL1 (0.62) L3MBTL1DAOMETNPC1RAB9A
SCHEMBL13197072 0.82 L3MBTL1 (0.66) L3MBTL1S1PR1S1PR3DAOMET
SCHEMBL7411441 0.82 L3MBTL1 (0.71) L3MBTL1S1PR1S1PR3DAOMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119390668-A Compound with ketoxime ether structure and application thereof 复旦大学 2025-02-07 CN disclosed
EP-2754660-B1 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2016-11-02 EP disclosed
EP-2754660-B1 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2016-11-02 EP disclosed
US-9284300-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2016-03-15 US disclosed
US-9284300-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2016-03-15 US disclosed
US-20150038534-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2015-02-05 US disclosed
US-20150011534-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2015-01-08 US disclosed
US-20150011534-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2015-01-08 US disclosed
US-20150011534-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2015-01-08 US disclosed
US-8927540-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2015-01-06 US disclosed
WO-2010078905-A1 BENZOTHIAZOLONE DERIVATIVE MERCK PATENT GMBH (DE) 2010-07-15 WO disclosed
EP-2181111-A1 THIADIAZINONE DERIVATIVES Merck Patent GmbH (DE) 2010-05-05 EP disclosed
EP-2164843-A1 PYRIDAZINONE DERIVATES Merck Patent GmbH (DE) 2010-03-24 EP disclosed
EP-2150551-A1 2-OXO-3-BENZYL-BENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS MET KINASE INHIBITORS FOR THE TREATMENT OF TUMORS Merck Patent GmbH (DE) 2010-02-10 EP disclosed
WO-2009030333-A1 THIADIAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2009-03-12 WO disclosed
WO-2009030333-A1 THIADIAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2009-03-12 WO disclosed
WO-2009006959-A1 PYRIDAZINONE DERIVATES MERCK PATENT GMBH (DE) 2009-01-15 WO disclosed
WO-2009006959-A1 PYRIDAZINONE DERIVATES MERCK PATENT GMBH (DE) 2009-01-15 WO disclosed
WO-2008148449-A1 2-OXO-3-BENZYL-BENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS MET KINASE INHIBITORS FOR THE TREATMENT OF TUMORS MERCK PATENT GMBH (DE) 2008-12-11 WO disclosed
WO-2008148449-A1 2-OXO-3-BENZYL-BENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS MET KINASE INHIBITORS FOR THE TREATMENT OF TUMORS MERCK PATENT GMBH (DE) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038534-A1 COMPOUNDS AND METHODS XDH, LPXN, CCNY L3MBTL1 499/4885S1PR1 2032/4885S1PR3 910/4885
US-20150011534-A1 PYRIDAZINONE DERIVATIVES MET, RET, ERBB2 L3MBTL1 971/4885S1PR1 1285/4885S1PR3 1355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.